1340 NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response

Slični predmeti

• 1340 NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response
  od: Scott Daigle, i dr.
  Izdano: (2023-11-01)
• 685 A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model
  od: David Ciccone, i dr.
  Izdano: (2020-11-01)
• HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results
  od: David A. Braun, i dr.
  Izdano: (2026-05-01)
• 751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor
  od: Scott Daigle, i dr.
  Izdano: (2023-11-01)
• Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
  od: Chan Gao, i dr.
  Izdano: (2021-01-01)